OPKO Health (OPK) Reports Q2 Loss Per Share of 2c, Revenue Beats

Go back to OPKO Health (OPK) Reports Q2 Loss Per Share of 2c, Revenue Beats

OPKO Health Reports First Quarter Financial and Operating Results

May 9, 2016 4:13 PM EDT

Consolidated Revenue Increased to $291.0 Million From $30.1 Million for the First Quarter of 2016 as compared to the 2015 period Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and OPKO Health Entered into Agreement for OPKOs RAYALDEE®; OPKO to Receive up to $282 Million in Upfront and Milestone Payments, Plus Tiered Double-Digit Royalties; Vifor Fresenius also Acquired an Option for Rights to the U.S. Dialysis Market for a New Dosage Form of RAYALDEE Which Provides for Payment to OPKO of up to $555 Million in Additional Milestone Payments Plus Double-Digit Royalties if Exercised... More